AR064635A1 - Derivados de benzotiazolona - Google Patents

Derivados de benzotiazolona

Info

Publication number
AR064635A1
AR064635A1 ARP070105801A ARP070105801A AR064635A1 AR 064635 A1 AR064635 A1 AR 064635A1 AR P070105801 A ARP070105801 A AR P070105801A AR P070105801 A ARP070105801 A AR P070105801A AR 064635 A1 AR064635 A1 AR 064635A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
ring
halogen
cycloalkyl
Prior art date
Application number
ARP070105801A
Other languages
English (en)
Inventor
Stephen Connolly
Alexander Humphries
Premji Meghani
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR064635A1 publication Critical patent/AR064635A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde Ra y Rb son, en forma independiente, hidrogeno o alquilo C1-3; o Ra y Rb, junto con el átomo de carbono al cual están unidos, forman un anillo ciclopropilo o ciclobutilo; R1 es: un alfa - o beta-alquilo C3-12 ramificado (opcionalmente sustituido por halogeno, alcoxi C1-6, alquiltio C1-6, alquil C1-6S(O), alquil C1-6S(O)2, haloalcoxi C1-6, hidroxi, NR26R27, OC(O)(C1-6 alquilo), cicloalquilo C3-12 o R28), CH2(C3-12 cicloalquilo) (estando el anillo cicloalquilo opcionalmente sustituido por halogeno, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquil C1-6S(O), alquil C1-6S(O)2, haloalcoxi C1-6, hidroxi, NR26R27, OC(O)(C1-6 alquilo), cicloalquilo C3-12 o R28), cicloalquilo C3-12 (opcionalmente sustituido por halogeno, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquil C1-6S(O), alquil C1-6S(O)2, haloalcoxi C1-6, hidroxi, NR26R27, OC(O)(C1-6 alquilo), cicloalquilo C3-12 o R28) o R28; R6 es un sistema de anillo aromático o heteroaromático de 5 a 14 miembros que está opcionalmente sustituido por halogeno, hidroxi, carboxilo, alquilo C1-6 (opcionalmente sustituido por halogeno o -NR7R8), alcoxi C1-6(opcionalmente sustituido por halogeno o -NR9R10), cicloalquilo C3-6, alcoxicarbonilo C1-6, -NR11R12, alquilcarbonilamino C1-6, alquilsulfonilamino C1-6, fenilsulfonilamino, -C(O)NHR13, -SO2NHR14, alquil C1-6S(O)p (opcionalmente sustituido por halogeno), alquenilo C2-4, alquinilo C2-4, ciano o alquil C0-6-R15, o un anillo fenilo o heteroaromático de 5 o 6 miembros (cada uno de los cuales está opcionalmente sustituido por halogeno, trifluorometilo, hidroxi, alquilo C1-6, alcoxi C1-6 o -NR16R17); R6 también puede ser haloalquilo C1-6; p es 0, 1 o 2; R13 es hidrogeno, alquilo C1-6, fenil-C0-6 alquilo o alquileno C2-6-NR18R19; ambos R18 y R19 son, en forma independiente, hidrogeno o alquilo C1-6, o R18 y R19 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo adicional en el anillo seleccionado entre nitrogeno y oxigeno; R14 es hidrogeno, alquilo C1-6, fenil-C0-6 alquilo o alquileno C1-6-NR20R21; R15 es un anillo saturado de 5 o 6 miembros que contiene nitrogeno; R2, R3, R5, R7, R8, R9, R10, R11, R12, R16, R17, R26, R27 y R29 son, en forma independiente, hidrogeno o alquilo C1-6; R4 es hidrogeno, hidroxi o alquilo C1-6; ambos R20 y R21 son, en forma independiente, hidrogeno o alquilo C1-6, o R20 y R21 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo adicional en el anillo seleccionado entre nitrogeno y oxígeno; R28 es un heterociclilo de 4 a 7 miembros que comprende un nitrogeno en el anillo (opcionalmente sustituido por C(O)(alquilo C1-6), oxígeno o azufre; estando el anillo R28 opcionalmente sustituido por alquilo C1-6, y los átomos de carbono del anillo que no son adyacentes a un heteroátomo en el anillo están opcionalmente sustituidos con halogeno, alcoxi C1-6, alquiltio C1-6, alquil C1-6S(O), alquil C1-6S(O)2, haloalcoxi C1-6, hidroxi, NR18R19, OC(O)(alquilo C1-6) o cicloalquilo C3-12; o una sal aceptable para uso farmacéutico del mismo.
ARP070105801A 2006-12-20 2007-12-20 Derivados de benzotiazolona AR064635A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87092206P 2006-12-20 2006-12-20
US91004507P 2007-04-04 2007-04-04
US95198007P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR064635A1 true AR064635A1 (es) 2009-04-15

Family

ID=39167020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105801A AR064635A1 (es) 2006-12-20 2007-12-20 Derivados de benzotiazolona

Country Status (21)

Country Link
US (3) US20100022491A1 (es)
EP (1) EP2121642B1 (es)
JP (1) JP2010513440A (es)
KR (1) KR20090091342A (es)
AR (1) AR064635A1 (es)
AT (1) ATE517879T1 (es)
AU (1) AU2007336075B2 (es)
BR (1) BRPI0722096A2 (es)
CA (1) CA2672811A1 (es)
CL (1) CL2007003765A1 (es)
CO (1) CO6190554A2 (es)
EC (1) ECSP099426A (es)
HK (1) HK1136572A1 (es)
IL (1) IL199014A0 (es)
MX (1) MX2009006009A (es)
NO (1) NO20092691L (es)
PE (1) PE20081544A1 (es)
SA (1) SA07280728B1 (es)
TW (1) TW200833670A (es)
UY (1) UY30808A1 (es)
WO (1) WO2008075026A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
JP2011520877A (ja) * 2008-05-13 2011-07-21 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102124003A (zh) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 作为治疗呼吸***疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物
AU2009260904A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653977A (en) * 1953-09-29 Chxnx
US3775477A (en) * 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
AU581887B2 (en) 1984-04-17 1989-03-09 Glaxo Group Limited Ethanolamine compounds
US4554287A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones
US4554284A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
JPH03133946A (ja) 1989-10-10 1991-06-07 Glaxo Group Ltd フェンエタノールアミン化合物
US5648370A (en) * 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
ATE209192T1 (de) 1996-05-20 2001-12-15 Teijin Ltd Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
SE9700706D0 (sv) 1997-02-27 1997-02-27 Astra Pharma Prod Process for the preparation of benzothiazoline compounds
SE9701304D0 (sv) 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
KR100912324B1 (ko) 2001-09-14 2009-08-14 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
EP1751086A2 (en) 2004-06-03 2007-02-14 Theravance, Inc. DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008512470A (ja) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20080125462A1 (en) 2005-01-11 2008-05-29 Lois Elizabeth Vernon Cinnamate Salts Of A Beta-2 Adrenergic Agonist
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
NZ585580A (en) 2005-07-18 2011-08-26 Pfizer Ltd Process for the preparation of sulfonamide derivatives
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
US20090029958A1 (en) * 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
WO2008041914A1 (en) 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
US20100056508A1 (en) 2006-12-20 2010-03-04 Astrazeneca Ab Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702458D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
KR20100103834A (ko) * 2007-12-20 2010-09-28 아스트라제네카 아베 분말 ８５４를 탈응집하는 장치 및 방법
AU2009260904A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity

Also Published As

Publication number Publication date
IL199014A0 (en) 2010-02-17
WO2008075026A1 (en) 2008-06-26
KR20090091342A (ko) 2009-08-27
BRPI0722096A2 (pt) 2014-04-01
US20100249200A1 (en) 2010-09-30
AU2007336075A1 (en) 2008-06-26
ECSP099426A (es) 2009-07-31
US20100022491A1 (en) 2010-01-28
SA07280728B1 (ar) 2010-12-01
NO20092691L (no) 2009-09-16
CA2672811A1 (en) 2008-06-26
US20080207698A1 (en) 2008-08-28
EP2121642B1 (en) 2011-07-27
US7700782B2 (en) 2010-04-20
CL2007003765A1 (es) 2008-08-22
MX2009006009A (es) 2009-06-16
AU2007336075B2 (en) 2011-10-27
EP2121642A1 (en) 2009-11-25
TW200833670A (en) 2008-08-16
JP2010513440A (ja) 2010-04-30
PE20081544A1 (es) 2009-01-11
HK1136572A1 (en) 2010-07-02
ATE517879T1 (de) 2011-08-15
UY30808A1 (es) 2008-07-31
CO6190554A2 (es) 2010-08-19

Similar Documents

Publication Publication Date Title
AR064635A1 (es) Derivados de benzotiazolona
AR088449A1 (es) Benzilindazoles sustituidos
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20160859A1 (es) Inhibidores de la quinasa reguladora de la senal de apoptosis
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
AR059494A1 (es) Derivados biciclicos de bisamida con actividad pesticida
AR063529A1 (es) Compuestos de pirazolina
AR076922A1 (es) Benzodiazepinas como inhibidores de pi3k/mtor, una composicion farmaceutica que las comprende, metodos para su fabricacion y su uso en el tratamiento del cancer.
PE20141974A1 (es) Compuestos de heterociclilo
AR071370A1 (es) Derivados tiazolicos peptidicos utiles como inhibidores de vhc y composiciones farmaceuticas que los contienen.
PE20051141A1 (es) Inhibidores de la polimerasa viral
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
AR055074A1 (es) Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas.
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR076002A1 (es) Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR095079A1 (es) Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CO6190528A2 (es) Inhibidores de la actividad de la akt
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal